SuperworthBolt Biotherapeutics BOLT
- Market cap
- $12.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $4.7M
- +13% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Bolt Biotherapeutics trades at 2.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $4.7M over the last twelve months, up 13% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.5M+20% | $2.1M+48% | $5.3M+189% | $1.3M−11% | $1.1M−55% | $0 | $1.2M−77% | $1.8M+42% | $2.2M+90% | $2.5M | $26K−98% | $5K−100% | |
| R&D | $15M−21% | $16.3M−3% | $16.5M+13% | $15.4M−1% | $13.8M−8% | $11.7M−28% | $9.5M−43% | $7.5M−51% | $6.5M−53% | $5M−57% | $4.8M−49% | $5.1M−31% |
| SG&A | $5.8M+5% | $5.5M−1% | $5.8M+4% | $4.9M−13% | $3.8M−34% | $3.9M−29% | $3.8M−35% | $3.5M−28% | $3.3M−12% | $3.1M−21% | $2.8M−27% | $2.4M−31% |
| −$18.2M−19% | −$19.8M−6% | −$17.1M−7% | −$22.6M+14% | −$16.4M−10% | −$16.9M−14% | −$12.1M−29% | −$9.2M−59% | −$7.7M−53% | −$7.1M−58% | −$7.6M−37% | −$8.4M−9% | |
| Net income | −$16.3M−25% | −$17.9M−11% | −$10.8M−36% | −$21.2M+17% | −$15.2M−7% | −$15.9M−11% | −$11M+2% | −$8.6M−60% | −$7.1M−53% | −$6.6M−58% | −$7.2M−34% | −$7.7M−10% |
| −$8.60−26% | −$9.40−11% | −$5.60−38% | −$11.12+16% | −$7.93−8% | −$8.32−12% | −$5.76+3% | −$4.46−60% | −$3.72−53% | −$3.84−54% | −$4.31−25% | −$4.57+3% | |
| 1.9M+1% | 1.9M+1% | 1.9M+1% | 1.9M+1% | 1.9M+1% | 1.9M+1% | 1.9M+1% | 1.9M+1% | 1.9M+0% | 1.7M−10% | 1.7M−12% | 1.7M−12% |
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Bolt Biotherapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BOLTBolt Biotherapeutics | $12.1M | n/m | n/a | 2.6× | +13% | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Bolt Biotherapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .